Description
Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C49H66N10O10S2—Basic Clin Pharmacol Toxicol. 2022 Jun 10.|Cell Mol Bioeng. 2022.|Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec.|J Pharm Biomed Anal. 11 December 2021, 114518.|J Pharm Biomed Anal. 2022: 115156.|J Pharm Sci. 2022 Oct 10;S0022-3549(22)00454-3.|Nat Commun. 2023 Feb 21;14(1):962.|Research Square Print. 2022 Aug.-[1]Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118|[2]Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934.|[3]Xiao-Xia Wang,et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118.–83150-76-9–1019.24–99.64–O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45–Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease–H2O : 100 mg/mL (ultrasonic)–Apoptosis;Somatostatin Receptor–SSTR2;SSTR3;SSTR5–Apoptosis;GPCR/G Protein;Neuronal Signaling–Peptides
